Comparative Pharmacology
Head-to-head clinical analysis: DIFLUCAN versus TIOCONAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFLUCAN versus TIOCONAZOLE.
DIFLUCAN vs TIOCONAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diflucan (fluconazole) is a triazole antifungal agent that inhibits fungal cytochrome P450 14-alpha-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability and inhibition of fungal growth.
Inhibition of fungal CYP450-dependent 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Oral or IV: 200-400 mg loading dose, then 100-200 mg once daily. Dose and duration depend on indication.
Topical: Apply 1% cream, lotion, or solution to affected area twice daily for 2-4 weeks. Vaginal: Insert 1 applicatorful of 6.5% ointment intravaginally at bedtime as a single dose.
None Documented
None Documented
Clinical Note
moderateTioconazole + Tranilast
"The risk or severity of adverse effects can be increased when Tioconazole is combined with Tranilast."
Clinical Note
moderateTioconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Tioconazole is combined with Tolfenamic acid."
Clinical Note
moderateTioconazole + Nimesulide
"The risk or severity of adverse effects can be increased when Tioconazole is combined with Nimesulide."
Clinical Note
moderateTioconazole + Risedronic acid
30 hours (range 20-50 hours); prolonged in renal impairment (up to 98 hours in CrCl <20 mL/min)
Terminal elimination half-life is approximately 24–30 hours after topical application, reflecting slow systemic clearance of absorbed fraction.
Renal: 80% unchanged; fecal/biliary: 11% as metabolites
Primarily fecal (minimally absorbed; <5% absorbed dose excreted renally as metabolites); topically applied tioconazole is largely unabsorbed.
Category C
Category A/B
Antifungal
Antifungal
"The risk or severity of adverse effects can be increased when Tioconazole is combined with Risedronic acid."